Mezlocillin for treatment of infections in cancer patients.
Mezlocillin, at a dose of 3 g intravenously over a 2-h period every 4 h, was used for the treatment of 92 episodes of documented infections in 75 myelosuppressed cancer patients. The response rate in 59 evaluable bacterial infections was 46%. Eight of 23 patients with septicemia (35%) responded. The...
Guardat en:
| Publicat a: | Antimicrob Agents Chemother |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Microbiology (ASM)
1980
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC283920/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6447474/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.17.6.1008 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|